Dermatology:

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

Abstracts from the 36th Nordic Congress of Dermatology and Venereology.

Abstract: Atopic dermatitis (AD) is a chronic inflammatory skin condition thought to be impacted by several risk factors, from genetics to lifestyle. Diet is a lifestyle factor that is of great interest for patients and providers. While there are several diet-related studies that have aimed to understand which dietary patterns and triggers are associated with AD, there exists some conflicting evidence that makes dietary recommendations and decisions difficult and can put patients at risk of inadequate nutrition. A review of dietary patterns and supplements revealed that the most consistent and beneficial dietary patterns associated with improvements in AD were supplementation with probiotics and n-3 polyunsaturated fatty acids and reductions in sodium intake. Data for other diets and supplements like antioxidants and various vitamins were more inconclusive, supporting the need for more high-quality dietary research. Dietary changes have the potential to positively impact the management of AD and should be made in conjunction with a provider to ensure nutritional needs are met.

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

No abstract available

Advances in inflammatory skin disease management are rapidly redefining dermatologic practice. This issue presents a compelling framework unifying type 2 inflammation across conditions like atopic dermatitis, prurigo nodularis, and chronic urticaria, emphasizing shared cytokine pathways and therapeutic opportunities. Also featured here is new real-world evidence supporting dupilumab efficacy following tralokinumab failure. In psoriasis, a novel "step-down" treatment strategy advocates for earlier biologic use in younger patients, followed by de-escalation. A paired commentary tempers this proposal with methodological and practical concerns. Finally, data on bimekizumab's safety and effectiveness in patients with chronic kidney disease address a critical clinical gap. These contributions highlight a shift toward precision medicine, integrating immunologic insight with patient age, comorbidity profiles, and therapeutic sequencing to inform truly individualized care.

No abstract available

No abstract available

No abstract available

No abstract available